18F-FDG versus 68Ga-FAPI-46 as PET tracer in ER-positive breast cancer - a pilot study

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508066-15-01

Enrollment

Registered

2025-03-18

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hormone-positive breast cancer

Brief summary

The proportion of discordant pairs: How many lesions are detected on the 68Ga-FAPI-46 PET scan but not on the 18F-FDG PET scan and how many lesions are detected on the 18F-FDG PET scan but not on the 68Ga-FAPI-46 PET scan?

Detailed description

To investigate the proportion of 68Ga-FAPI-46-positive 18F-FDG-negative lesions for which performing a biopsy is not feasible.

Interventions

DRUGSteripet 250 MBq/ml Oplossing voor injectie

DRUG68Ga-FAPI-46

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The proportion of discordant pairs: How many lesions are detected on the 68Ga-FAPI-46 PET scan but not on the 18F-FDG PET scan and how many lesions are detected on the 18F-FDG PET scan but not on the 68Ga-FAPI-46 PET scan?	—

Secondary

Measure	Time frame
To investigate the proportion of 68Ga-FAPI-46-positive 18F-FDG-negative lesions for which performing a biopsy is not feasible.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026